Navigation Links
AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
Date:7/8/2009

    GAI-122, an investigational injectable nano-emulsion formulated with
    AlphaRx's proprietary drug delivery technology, provides significant
    hepatoprotection in multiple animal models of acute hepatitis suggesting
    that GAI-122 may reduce necro-inflammation and may halt disease
    progression to fibrosis or cirrhosis.

MARKHAM, ON, July 8 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) today reported positive preclinical results on GAI-122 injectable nano-emulsion in multiple models of acute hepatitis, an inflammatory liver disease.

GAI-122 significantly reduced Aminotransferase (ALT), an enzyme released into the blood that indicates damage to the liver, following IP administration in three different preclinical models of acute liver injury. Very high levels of ALT are usually due to acute hepatitis or a viral infection.

In the a-Fas model of liver injury, GAI-122 markedly reduced ALT levels by 90% from baseline, where control ALT values were ~22,000 IU/L. Significant efficacy was also demonstrated in the rat TNFa/Gln model and in the Drug-induced liver injury (DILI) model.

"DILI accounts for more than 50% of acute liver failure and there are no satisfactory treatment options currently available. The excellent efficacy data demonstrated by these studies suggest that GAI-122 may represent a potential first line treatment option for patients with liver disease", stated Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx.

In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all development costs.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
2. AlphaRx Shareholder Update
3. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
4. AlphaRx Signs Cooperative Research and Development Agreement with US Army
5. AlphaRx Provides Corporate and Development Update
6. AlphaRxs Indaflex(TM) Continues its Clinical Development
7. AlphaRx CEO Accumulates More Company Shares
8. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
9. AlphaRx Announces Debt Conversion
10. AlphaRx To Present at 47th Annual ICAAC
11. Recent News Reports of Sweetener Reformulations Raise Questions About Motivations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... help you brush more effectively even on the go. Their electric toothbrushes aggressively ... and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology with ...
(Date:9/22/2017)... Diego, CA (PRWEB) , ... September 22, 2017 ... ... offer groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, ... Smart Mart has stated to offer wearable, and customers can find clothing at ...
(Date:9/21/2017)... ... ... With ProSlideshow Portrait from Pixel Film Studios creating a stylistic portrait slideshow ... to two layers of subject matter along with fully customizable backdrop animation, key-frameless animation, ... Pro X. , With ProSlideshow Portrait each user are given the tools and ...
(Date:9/21/2017)... IL (PRWEB) , ... September 21, 2017 , ... SABRE ... to run from September 11 to the end of November. , The Chicago, Illinois, ... to their community and teach them about the ease of taking their personal safety ...
(Date:9/21/2017)... ... 21, 2017 , ... Hair restoration surgery is having a ... the International Society of Hair Restoration Surgery (ISHRS). The worldwide volume ... with 635,189 procedures performed in 2016. , "Like other forms of cosmetic ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... Sept. 8, 2017 ... MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th ... offering free MRI brain scans to the public.Where:  ... parked at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, ...
(Date:9/7/2017)... Calif. , Sept. 7, 2017  For nearly two decades, New ... in the Assisted Reproduction Insurance industry. Today, New Life Agency announces a ... medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
Breaking Medicine Technology: